EXTRANODAL NK/T-CELL LYMPHOMA
Clinical trials for EXTRANODAL NK/T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL NK/T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for EXTRANODAL NK/T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo may outperform chemo in rare lymphoma
Disease control Not yet recruitingThis Phase 3 trial tests whether an immunotherapy-based regimen (sintilimab, pegaspargase, and anlotinib) works better than standard chemotherapy before a stem cell transplant in people with newly diagnosed, advanced extranodal NK/T-cell lymphoma. Participants are randomly assign…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Rong Tao • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New hope for rare blood cancer: drug combo targets relapsed lymphoma
Disease control Not yet recruitingThis study tests whether adding the drug sugemalimab to standard chemotherapy can help adults with a rare type of blood cancer (NK/T-cell lymphoma) that has returned or stopped responding to previous treatment. About 150 participants will receive either the new combination or a p…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Promising combo may slash radiation harm in rare lymphoma
Disease control Not yet recruitingThis study tests whether adding the drug selinexor to a lower dose of radiation can treat early-stage NK/T-cell lymphoma just as well as standard high-dose radiation, but with fewer side effects. About 34 people who have not had prior treatment will receive chemotherapy first, th…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New cocktail of drugs shows promise against rare lymphoma
Disease control Not yet recruitingThis study is testing a combination of three drugs—sintilimab, chidamide, and azacitidine—as a first treatment for people with early-stage extranodal NK/T-cell lymphoma, a rare blood cancer. About 30 participants will receive the drugs, and their response will guide further treat…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo shows promise for rare blood cancer
Disease control Not yet recruitingThis study tests whether adding the drug golidocitinib to standard chemotherapy and immunotherapy works better than the standard treatment alone for people with advanced NK/T-cell lymphoma, a rare blood cancer. About 40 adults will be randomly assigned to one of two groups. The m…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: WEI XU • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC